Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1Phase 2 1

Status

Recruiting 4Unknown 3Withdrawn 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

NET 3Endocrine 3Gastrointestinal 1

Conditions

Neuroendocrine Tumors 2Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Cisplatin 352Oxaliplatin 262Capecitabine 258Radiotherapy 240Gemcitabine 223Docetaxel 223Carboplatin 223Drug Therapy 219Cyclophosphamide 219Paclitaxel 205apatinib 201Bevacizumab 196camrelizumab 190Fluorouracil 188sintilimab 133Irinotecan 125Blood Specimen Collection 125Dexamethasone 123Etoposide 119Radiosurgery 118toripalimab 117Surgical Procedures, Operative 115pembrolizumab 112Pemetrexed 108anlotinib 105S 1 (combination) 105Leucovorin 102Surveys and Questionnaires 101Nivolumab 98tislelizumab 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × OTHER × 177Lu-octreotide, DOTA(0)-Tyr(3)- × Clear all
NCT05359146 2024-04-19

Beta plus

University Hospital, Basel, Switzerland

Phase EARLY_PHASE1 Unknown
16 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT04790708 2021-03-10

FENET-2016

University Hospital of Ferrara

Phase NA Unknown
250 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT04194125 2020-11-04

Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer

University of Warmia and Mazury

Phase 2 Unknown
25 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡